Sarah Sammons, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Email address sarah.sammons@duke.edu

Education and Training

College/University
University of Delaware

Medical School
Sidney Kimmel Medical College - Thomas Jefferson University

Residency
University of Maryland

Career and Research Goals

My career focus is in the treatment of women with aggressive sub-types of breast cancer such as basal-like (triple negative) and ERBB-2 amplified. My current research goals are finding therapeutic strategies to target the ERBB family of receptors specifically EGFR and ERBB3 in basal-like breast cancer. I hope to characterize the role somatic ERBB3 mutations in primary and metastatic basal type breast cancer. I also have a special interest in early phase drug development and toxicity management.

Honors, awards and distinctions

Alpha Omega Alpha Honor Society

Education and Training

  • Hematology-Oncology Fellowship, Duke University School of Medicine, 2015 - 2018
  • Internal Medicine Residency, University of Maryland School of Medicine, 2012 - 2015
  • M.D., Jefferson Medical College of Thomas Jefferson University, 2012

Publications

Zhu, Li, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, et al. “Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors..” J Immunother Cancer 7, no. 1 (October 18, 2019). https://doi.org/10.1186/s40425-019-0755-1.

PMID
31627744
Full Text

Sambade, Maria J., Grace Prince, Allison M. Deal, Dimitri Trembath, Megan McKee, Amy Garrett, Kevin Keith, et al. “Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases..” Breast Cancer Res Treat 176, no. 2 (July 2019): 321–28. https://doi.org/10.1007/s10549-019-05211-1.

PMID
31016641
Full Text

Dent, Susan, Chiara Melloni, Josee Ivars, Sarah Sammons, and Gretchen Kimmick. “Cardiotoxicities of Modern Treatments in Breast Cancer..” Curr Treat Options Cardiovasc Med 21, no. 7 (June 15, 2019). https://doi.org/10.1007/s11936-019-0738-z.

PMID
31203459
Full Text

Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Target Oncol 14, no. 1 (February 2019): 1–12. https://doi.org/10.1007/s11523-018-0587-9.

PMID
30136059
Full Text

Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer..” Target Oncol 14, no. 1 (February 2019). https://doi.org/10.1007/s11523-018-0614-x.

PMID
30535552
Full Text

Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype..” Clin Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.

PMID
29615305
Full Text

Narloch, Jessica L., S Harrison Farber, Sarah Sammons, Frances McSherry, James E. Herndon, Jenny K. Hoang, Fang-Fang Yin, et al. “Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis..” Neuro Oncol 19, no. 10 (October 1, 2017): 1391–97. https://doi.org/10.1093/neuonc/nox090.

PMID
28472527
Full Text

Sammons, Sarah L., Donna L. Topping, and Kimberly L. Blackwell. “HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles..” Curr Cancer Drug Targets 17, no. 7 (2017): 637–49. https://doi.org/10.2174/1568009617666170330120452.

PMID
28359238
Full Text

Witkiewicz, A. K., A. Dasgupta, S. Sammons, O. Er, M. B. Potoczek, F. Guiles, F. Sotgia, J. R. Brody, E. P. Mitchell, and M. P. Lisanti. “Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.” Cancer Biology and Therapy 10, no. 2 (July 15, 2010): 135–43. https://doi.org/10.4161/cbt.10.2.11983.

Full Text